CSL (CSJA) AI Stock Analysis

CSL

(Frankfurt:CSJA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Integrated biotherapy platformCSL’s vertically integrated plasma model links collection with specialty biotherapy manufacturing, helping support supply control, product availability, and operating efficiency. Combined with global commercialization across rare diseases and vaccines, this creates a durable platform serving recurring medical needs.

Negative Factors

Large impairments and statutory lossThe scale of FY’26 impairments and the resulting statutory loss materially weaken reported earnings quality and reduce the equity cushion. Although largely noncash, these charges signal that parts of the asset base and prior investments have lost value, increasing execution and capital-allocation risk.

CSL (CSJA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 137.04B
Dividend Yield: 1.98%
Average Volume (3M): 300
Price to Earnings (P/E): -26.7
Beta (1Y): 0.49
Revenue Growth: -5.20%
EPS Growth: -180.92%
Country: Germany
Employees: 29,000
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

CSL Business Overview & Revenue Model

Company Description

CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international...

CSL Earnings Call Summary

Earnings Call Date:Aug 16, 2026(Q4-2026)|% Change Since:51.81%|Next Earnings Date:Feb 08, 2027

Earnings Call SentimentNeutral

The call presents a mixed picture: operational and commercial turnaround actions are beginning to show early, tangible benefits (strong cash flow, successful transformation savings, Seqirus market outperformance, Ig momentum and promising product launches), but these positives are offset by very large impairments, significant and structural headwinds in Vifor (expected ~25% revenue decline in FY'27), continued albumin pricing pressure in China and an FY'26 statutory loss driven by noncash charges. Management’s FY'27 underlying guidance (NPAT +~5% cc; Behring growth) and capital returns indicate confidence in a return to profitable growth, yet the scale of recent impairments and the outlook for Vifor mean near-term headwinds remain material.

Positive Updates

Strong cash generation and capital returns

Operating cash flow of $3.5 billion supported completion of an AUD 1.0 billion share buyback, a new AUD 1.1 billion buyback authorization for FY'27, and maintenance of the full-year dividend at $2.92 per share (U.S. dollar basis); net debt/EBITDA finished at 1.8x within target range.

Negative Updates

Very large impairments and statutory loss

Total pretax impairments of $7.1 billion for FY'26 (including $5.5 billion in H2), with a $4.1 billion impairment primarily related to Vifor. After restructuring and impairments, statutory NPAT attributable to CSL shareholders was a loss of $2.6 billion.

Company Guidance

CSL guided FY '27 group revenue to be broadly in line with FY '26 (FY '26 revenue $15.8bn, -1% cc) and expects underlying NPAT (excluding restructuring and impairments) to grow by approximately 5% at constant currency (noting an estimated FX headwind of about $50m at current rates). By business, CSL Behring is expected to deliver mid‑single‑digit revenue growth with immunoglobulin growing mid‑ to high‑single digits and a modest gross‑margin improvement, Seqirus low‑single‑digit revenue growth, and CSL Vifor a ~25% revenue decline (no TAVNEOS sales included in guidance). The transformation program should deliver ~ $220m incremental savings in FY '27 (building on $176m delivered in FY '26) taking annualized savings to ~ $400m and up to $550m in FY '28, with roughly half the incremental savings to be reinvested; FY '27 CapEx is expected to be about $1.0bn ± $100m. Capital return and balance‑sheet items include a new share buyback of ~AUD 1.1bn, the dividend maintained in US$ (FY '26 full‑year $2.92 per share, final $1.62), and a target net‑debt/EBITDA range of 1.5–2x.

CSL Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:CSJA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	81Outperform	$95.51B	19.76	15.07%	0.40%	18.59%	8.14%
ARGX	76Outperform	$56.88B	42.37	16.86%	―	70.57%	30.28%
BMRN	61Neutral	$11.33B	153.97	1.18%	―	13.69%	-89.03%
MRNA	55Neutral	$88.52B	-27.78	-39.20%	―	-27.62%	-6.22%
BNTX	53Neutral	$22.15B	-11.50	-9.16%	―	-1.05%	-395.95%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:CSJA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:CSJA	Csl Ltd	30.00	6.19	26.01%
BMRN	Biomarin Pharmaceutical Inc.	58.51	5.66	10.71%
REGN	Regeneron Pharmaceuticals	927.89	288.92	45.22%
ARGX	Argenx	892.87	66.59	8.06%
MRNA	Moderna	221.72	196.81	790.08%
BNTX	Biontech Se Sponsored Adr	88.17	-15.78	-15.18%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

CSL AI Stock Analysis